Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients.
作者信息
Delamain M T, Miranda E C M, Lourenço G J, de Souza C A, Lima C S P
机构信息
Hematology and Hemotherapy Center, University of Campinas, Sao Paulo, Brazil.
Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Sao Paulo, Brazil.
出版信息
Blood Cancer J. 2017 Apr 28;7(4):e560. doi: 10.1038/bcj.2017.38.
Abstract
摘要
相似文献
1
Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients.通过转化性前瞻性研究，GSTP1基因Ile105Val多态性成为初发性大B细胞淋巴瘤患者的预后标志物。
Blood Cancer J. 2017 Apr 28;7(4):e560. doi: 10.1038/bcj.2017.38.
2
Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.TP53基因rs1625895多态性对弥漫性大B细胞淋巴瘤（DLBCL）患者的预后影响
Br J Haematol. 2015 Apr;169(1):32-5. doi: 10.1111/bjh.13237. Epub 2014 Nov 28.
3
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.ACVBP 强化化疗联合利妥昔单抗对比标准 CHOP 联合利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤（LNH03-2B）：一项开放标签、随机、3 期临床试验。
Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4.
4
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.p53 异常对接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者的预后影响。
Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.
5
CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.初发弥漫性大B细胞淋巴瘤中CD30的表达：一项来自不列颠哥伦比亚省的基于人群的研究。
Br J Haematol. 2014 Dec;167(5):608-17. doi: 10.1111/bjh.13085. Epub 2014 Aug 19.
6
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.在德国高级非霍奇金淋巴瘤研究组的前瞻性临床试验中，针对弥漫性大 B 细胞淋巴瘤进行治疗，探讨了细胞起源分类和 MYC/BCL2 双表达状态的临床影响。
J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.
7
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.剂量调整的环磷酰胺、阿霉素、长春新碱和强的松联合利妥昔单抗化疗在预后不良的未经治疗的老年弥漫性大B细胞非霍奇金淋巴瘤患者中的活性和安全性
Cancer. 2011 Aug 1;117(15):3530; author reply 3531. doi: 10.1002/cncr.25948. Epub 2011 Feb 1.
8
Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.通过基因表达谱分析进行淋巴瘤细胞起源分类在广泛的实验室环境中具有临床意义。
Br J Haematol. 2018 Apr;181(2):272-275. doi: 10.1111/bjh.14556. Epub 2017 Feb 15.
9
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.80 岁以上弥漫性大 B 细胞淋巴瘤患者的减毒免疫化疗方案（R-miniCHOP）：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7.
10
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.在预后不良的未经治疗的弥漫性大 B 细胞非霍奇金淋巴瘤的非常老年患者中，使用利妥昔单抗的剂量调整的输注环磷酰胺、多柔比星、长春新碱和泼尼松化疗的活性和安全性。
Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.
本文引用的文献
1
Predictive potential role of glutathione S-transferases polymorphisms in response to chemotherapy and breast cancer prognosis.谷胱甘肽S-转移酶基因多态性在化疗反应及乳腺癌预后中的预测潜在作用
Genet Mol Res. 2015 Dec 11;14(4):16675-81. doi: 10.4238/2015.December.11.15.
2
Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.日本早期乳腺癌患者中谷胱甘肽S-转移酶P1（GSTP1）基因多态性与发热性中性粒细胞减少症之间的药物遗传学关联
Breast Cancer. 2016 Mar;23(2):195-201. doi: 10.1007/s12282-014-0547-x. Epub 2014 Jul 10.
3
Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma.血清β2-微球蛋白在非霍奇金淋巴瘤患者中的预后意义。
Oncology. 2014;87(1):40-7. doi: 10.1159/000362670. Epub 2014 Jun 25.
4
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab.免疫调节蛋白和代谢酶编码基因多态性对利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤患者的易感性和结局的影响。
Leuk Lymphoma. 2013 Oct;54(10):2205-14. doi: 10.3109/10428194.2013.774392. Epub 2013 Apr 2.
5
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.环磷酰胺代谢途径中的基因多态性、治疗相关毒性与 SWOG8897 乳腺癌临床试验中的无病生存
Clin Cancer Res. 2010 Dec 15;16(24):6169-76. doi: 10.1158/1078-0432.CCR-10-0281.
6
Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma.谷胱甘肽-S-转移酶基因型影响韩国弥漫性大B细胞淋巴瘤患者化疗相关毒性的风险及预后。
Cancer Genet Cytogenet. 2010 Apr 1;198(1):40-6. doi: 10.1016/j.cancergencyto.2009.12.004.
7
Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.药物重点：与基于环磷酰胺的治疗相关的药物遗传学研究。
Pharmacogenomics. 2009 Dec;10(12):1897-903. doi: 10.2217/pgs.09.134.
8
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
Blood. 2009 Apr 2;113(14):3307-13. doi: 10.1182/blood-2008-03-148874. Epub 2008 Sep 3.
9
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma.谷胱甘肽-S-转移酶基因型影响滤泡性非霍奇金淋巴瘤的预后。
Leuk Lymphoma. 2007 Mar;48(3):564-9. doi: 10.1080/10428190601158647.
10
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.对于接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者，修订后的国际预后指数（R-IPI）比标准IPI能更好地预测预后。
Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14.
Zotero 插件